We are often contacted by researchers who are looking for patients with certain conditions to take part in different types of research projects, from surveys to clinical trials. Please check this page regularly to see what opportunities might be available for you to get involved in and help further the search for better treatments and for cures. For US clinical trials please visit clinicaltrials.gov.
Please discuss potential participation in clinical trials with your specialist!
Note: this list does not constitute any form of recommendation and is not a complete list. To ensure you have all the facts, speak with your specialist. AMEND cannot be held liable for information on external websites.
PROJECTS BY AMEND AND ASSOCIATED ORGANISATIONS
- The UK Research Registry for Multiple Endocrine Neoplasia Type 1 (MEN1) and Pancreatic Neuroendocrine Tumour (PNET) - UK patients only
- MD Anderson (USA) GEN Registry for Multiple Endocrine Neoplasia Type II - international
CLINICAL TRIALS INFORMATION - MEN1
-
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)
- MEN1 Pancreatic NET: Chemotherapy (plus or minus Bevacizumab) - France
- MEN1 PNET, PHEO, PARA: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 (PRRT) in NETs - Europe & Australia
- MEN1 PNET: Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT (Lu-Ca-S) - Italy
- COMPETE: phase III clinical trial for patients with grade 1 and grade 2 neuroendocrine tumors of gastroenteric or pancreatic origin (G1+G2 GEP-NETs) COMPOSE: upcoming phase III clinical trial for patients with high G2+G3 GEP-NETs
CLINICAL TRIALS INFORMATION - PHEO/PARA
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)
- MEN1 PNET, PHEO, PARA: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 (PRRT) in NETs - Europe & Australia
- PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (pheo/para/MTC)
- FIRSTMAPPP International Randomised study in malignant progressive pheo and paraganglioma (Sunitinib vs placebo)
- PMT3 International multicentre prospective study that evaluates plasma and urinary biomarkers for prediction of malignancy and underlying germ-line mutations of tumour susceptibility genes in patients with pheo and paragangliomas
CLINICAL TRIALS INFORMATION - MEN2 and MTC
-
Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study) (PRED-AID)
- PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (pheo/para/MTC)
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) [Europe and Australia]
- Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104) [Europe]
- Phase 1/2 Study of LOXO-292 (selpercatinib) in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer (LIBRETTO-001) [worldwide]
- Phase 3 Study of selpercatinib (LOXO-292) in patients with RET-mutated medullary thyroid cancer (LIBRETTO-531) [worldwide]